Literature DB >> 25845865

In vivo pharmacokinetic/pharmacodynamic profiles of valnemulin in an experimental intratracheal Mycoplasma gallisepticum infection model.

Xia Xiao1, Jian Sun1, Tao Yang1, Xi Fang1, Dong Wu1, Yan Q Xiong2, Jie Cheng1, Yi Chen1, Wei Shi1, Ya-Hong Liu3.   

Abstract

Valnemulin, a semisynthetic pleuromutilin antibiotic derivative, is greatly active against Mycoplasma. The objective of our study was to evaluate the effectiveness of valnemulin against Mycoplasma gallisepticum in a neutropenic intratracheal model in chickens using a pharmacokinetic/pharmacodynamic (PK-PD) method. The PK of valnemulin after intramuscular (i.m.) administration at doses of 1, 10, and 20 mg/kg of body weight in M. gallisepticum-infected neutropenic chickens was evaluated by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Real-time PCR (RT-PCR) was used for quantitative detection of M. gallisepticum. The ratio of the 24-h area under the concentration-time curve divided by the MIC (AUC24/MIC) correlated well with the in vivo antibacterial effectiveness of valnemulin (R(2) = 0.9669). The AUC24/MIC ratios for mycoplasmastasis (a reduction of 0 log10 color-changing unit [CCU] equivalents/ml), a reduction of 1 log10 CCU equivalents/ml, and a reduction of 2.5 log10 CCU equivalents/ml are 28,820, 38,030, and 56,256, respectively. In addition, we demonstrated that valnemulin at a dose of 6.5 mg/kg resulted in a reduction of 2.5 log10 CCU equivalents/ml. These investigations provide a solid foundation for the usage of valnemulin in poultry with M. gallisepticum infections.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25845865      PMCID: PMC4468724          DOI: 10.1128/AAC.00200-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  30 in total

Review 1.  Age-related changes in pharmacokinetics.

Authors:  Shaojun Shi; Ulrich Klotz
Journal:  Curr Drug Metab       Date:  2011-09       Impact factor: 3.731

2.  Pharmacokinetics and bioavailability of valnemulin in broiler chickens.

Authors:  R Wang; L G Yuan; L M He; L X Zhu; X Y Luo; C Y Zhang; J J Yu; B H Fang; Y H Liu
Journal:  J Vet Pharmacol Ther       Date:  2011-06       Impact factor: 1.786

3.  Lack of antimicrobial bactericidal activity in Mycobacterium abscessus.

Authors:  Florian P Maurer; Vera L Bruderer; Claudia Ritter; Claudio Castelberg; Guido V Bloemberg; Erik C Böttger
Journal:  Antimicrob Agents Chemother       Date:  2014-04-21       Impact factor: 5.191

4.  Integration of pharmacokinetic and pharmacodynamic indices of valnemulin in broiler chickens after a single intravenous and intramuscular administration.

Authors:  Dong-Hao Zhao; Yu-Feng Zhou; Yang Yu; Wei Shi; Xue Yang; Xia Xiao; Hui Deng; Guilin Gary Qiao; Bing-Hu Fang; Ya-Hong Liu
Journal:  Vet J       Date:  2014-05-13       Impact factor: 2.688

Review 5.  Are pleuromutilin antibiotics finally fit for human use?

Authors:  Rodger Novak
Journal:  Ann N Y Acad Sci       Date:  2011-12       Impact factor: 5.691

6.  Vancomycin: we can't get there from here.

Authors:  Nimish Patel; Manjunath P Pai; Keith A Rodvold; Ben Lomaestro; George L Drusano; Thomas P Lodise
Journal:  Clin Infect Dis       Date:  2011-04-15       Impact factor: 9.079

Review 7.  The effect of pathophysiology on pharmacokinetics in the critically ill patient--concepts appraised by the example of antimicrobial agents.

Authors:  Stijn I Blot; Federico Pea; Jeffrey Lipman
Journal:  Adv Drug Deliv Rev       Date:  2014-07-15       Impact factor: 15.470

Review 8.  Bacterial pathogens in wild birds: a review of the frequency and effects of infection.

Authors:  Clare McW H Benskin; Kenneth Wilson; Keith Jones; Ian R Hartley
Journal:  Biol Rev Camb Philos Soc       Date:  2009-04-29

9.  Mycoplasma gallisepticum and Escherichia coli mixed infection model in broiler chickens for studying valnemulin pharmacokinetics.

Authors:  X Xiao; D H Zhao; X Yang; W Shi; H Deng; J Ma; S Zhang; Y H Liu
Journal:  J Vet Pharmacol Ther       Date:  2013-06-20       Impact factor: 1.786

10.  Pharmacokinetics of marbofloxacin in pigs after intravenous and intramuscular administration of a single dose of 8 mg/kg: dose proportionality, influence of the age of the animals and urinary elimination.

Authors:  M Schneider; A Paulin; F Dron; F Woehrlé
Journal:  J Vet Pharmacol Ther       Date:  2014-03-25       Impact factor: 1.786

View more
  11 in total

Review 1.  En Route towards European Clinical Breakpoints for Veterinary Antimicrobial Susceptibility Testing: A Position Paper Explaining the VetCAST Approach.

Authors:  Pierre-Louis Toutain; Alain Bousquet-Mélou; Peter Damborg; Aude A Ferran; Dik Mevius; Ludovic Pelligand; Kees T Veldman; Peter Lees
Journal:  Front Microbiol       Date:  2017-12-15       Impact factor: 5.640

2.  Integrated pharmacokinetic-Pharmacodynamic (PK/PD) model to evaluate the in vivo antimicrobial activity of Marbofloxacin against Pasteurella multocida in piglets.

Authors:  Qing Lin Zeng; Xian Mei; Jia Su; Xiao Hong Li; Wen Guang Xiong; Yan Lu; Zhen Ling Zeng
Journal:  BMC Vet Res       Date:  2017-06-15       Impact factor: 2.741

3.  The PK-PD Relationship and Resistance Development of Danofloxacin against Mycoplasma gallisepticum in An In Vivo Infection Model.

Authors:  Nan Zhang; Yuzhi Wu; Zilong Huang; Lihua Yao; Longfei Zhang; Qinren Cai; Xiangguang Shen; Hongxia Jiang; Huanzhong Ding
Journal:  Front Microbiol       Date:  2017-05-30       Impact factor: 5.640

4.  In vivo pharmacokinetic/Pharmacodynamic modeling of Enrofloxacin against Escherichia coli in broiler chickens.

Authors:  Xia Xiao; Lijie Jiang; Weixuan Lan; Yongjia Jiang; Zhiqiang Wang
Journal:  BMC Vet Res       Date:  2018-11-29       Impact factor: 2.741

5.  In vivo Pharmacokinetic and Pharmacodynamic (PK/PD) Modeling and Establishment of the PK/PD Cutoff of Florfenicol Against Pasteurella multocida in Ducks.

Authors:  Xia Xiao; Weixuan Lan; Yaqin Zhao; Ruichao Li; Yuan Liu; Juan Liu; Zhiqiang Wang
Journal:  Front Microbiol       Date:  2021-01-11       Impact factor: 5.640

6.  In vivo antimicrobial activity of marbofloxacin against Pasteurella multocida in a tissue cage model in calves.

Authors:  Changfu Cao; Ying Qu; Meizhen Sun; Zhenzhen Qiu; Xianhui Huang; Binbin Huai; Yan Lu; Zhenling Zeng
Journal:  Front Microbiol       Date:  2015-07-24       Impact factor: 5.640

7.  The PK/PD Interactions of Doxycycline against Mycoplasma gallisepticum.

Authors:  Nan Zhang; Xiaoyan Gu; Xiaomei Ye; Xun Wu; Bingxu Zhang; Longfei Zhang; Xiangguang Shen; Hongxia Jiang; Huanzhong Ding
Journal:  Front Microbiol       Date:  2016-05-04       Impact factor: 5.640

8.  Pharmacokinetic/Pharmacodynamic Profiles of Tiamulin in an Experimental Intratracheal Infection Model of Mycoplasma gallisepticum.

Authors:  Xia Xiao; Jian Sun; Tao Yang; Xi Fang; Jie Cheng; Yan Q Xiong; Ya-Hong Liu
Journal:  Front Vet Sci       Date:  2016-09-06

9.  In Vivo Pharmacokinetic/Pharmacodynamic Profiles of Danofloxacin in Rabbits Infected With Salmonella typhimurium After Oral Administration.

Authors:  Xia Xiao; Lin Pei; Li-Jie Jiang; Wei-Xuan Lan; Jia-Yu Xiao; Yon-Jia Jiang; Zhi-Qiang Wang
Journal:  Front Pharmacol       Date:  2018-04-17       Impact factor: 5.810

10.  Pharmacokinetic/pharmacodynamic (PK/PD) evaluation of tulathromycin against Haemophilus parasuis in an experimental neutropenic guinea pig model.

Authors:  Yongda Zhao; Li-Li Guo; Binghu Fang; Baotao Liu
Journal:  PLoS One       Date:  2018-12-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.